Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Kite Pharma, Inc. | d803283d8k.htm |
Exhibit 16.1
October 14, 2014
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, N. E.
Washington, D.C. 20549
Ladies and Gentlemen:
We have read Kite Pharma, Inc.’s statements included under Item 4.01 of its Form 8-K dated October 7, 2014, and we agree with such statements, except that we are not in a position to agree or disagree with the Company’s statements that the audit committee decided to engage Ernst & Young LLP to serve as the Company’s independent registered public accounting firm for the fiscal year December 31, 2014, and the statements made in the 5th paragraph.
/s/ Crowe Horwath LLP
Crowe Horwath LLP
New York, New York
| cc: | Mr. Jonathon Peacock |
Audit Committee Chairman
Kite Pharma, Inc.